Skip to content

Mobile Health Intervention in Increasing HPV Vaccine Coverage Among Young Adult Gay and Bisexual Men

Increasing HPV Vaccine Coverage Among Young Adult Gay and Bisexual Men

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02835755
Enrollment
150
Registered
2016-07-18
Start date
2016-07-11
Completion date
2017-04-16
Last updated
2017-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subject

Brief summary

This pilot trial studies how well a mobile health (mHealth) human papillomavirus (HPV) vaccine intervention works in increasing HPV vaccine coverage among young adult gay and bisexual men. Giving young men information about the HPV vaccine and the importance of vaccination may encourage them to get the HPV vaccine.

Detailed description

PRIMARY OBJECTIVES: I. Pilot test a mobile health (mHealth) HPV vaccine intervention for young gay and bisexual men to establish feasibility and acceptability. II. Obtain preliminary efficacy data on whether the mHealth HPV vaccine intervention increases HPV vaccine initiation compared to the control group. SECONDARY OBJECTIVES: I. Examine whether the mHealth HPV vaccine intervention affects secondary outcomes compared to the control group. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I (CONTROL): Patients receive standard information about HPV and HPV vaccine, such as the vaccine information statement (VIS), on a mobile-friendly website study portal. GROUP II (INTERVENTION): Patients receive the mHealth HPV vaccine intervention consisting of content about HPV and HPV vaccine on the study portal for 15 minutes and vaccination reminders sent by the portal via text or e-mail. All patients complete a survey on the study portal at baseline, immediately after the mHealth intervention or control materials, and at 3 months and 7 months thereafter for about 10-15 minutes each.

Interventions

OTHEREducational Intervention

Receive standard HPV and HPV vaccine information

OTHERSurvey Administration

Ancillary studies

Sponsors

Ohio State University Comprehensive Cancer Center
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* Self-identifies as gay or bisexual * Lives in the United States (US) * Has not received any doses of HPV vaccine

Design outcomes

Primary

MeasureTime frameDescription
Acceptability will be established by examining participant satisfaction with study materialsUp to 7 monthsLinear regression will be used and usage data and satisfaction with vaccination reminders (intervention group only) will be descriptively examined.
Feasibility established by achieving recruitment, retention, and medical record release goalsUp to 7 monthsCritical parameters with point estimates and 95% confidence intervals will be estimated and tested with a two-sided alpha=.05
Receipt of 1 or more doses of HPV vaccineUp to 7 monthsEvaluated using logistic regression.

Secondary

MeasureTime frameDescription
Changes in potential mediators between study group and HPV vaccination (i.e., protection motivation theory [PMT] constructs and HPV and HPV vaccine knowledge)Up to 7 monthsEvaluated using analysis of covariance models.
Receipt of second and third doses of HPV vaccineUp to 7 monthsEvaluated using logistic regression.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026